Intercept’s NASH Hopes: A Case Study For Implications Of US Pricing Bill

14 Jul 2022

• By Michael McCaughan

Interecept is reviving hopes that it will be able to capture a potential blockbuster indication for its liver disease drug Ocaliva. The development strategy might never happen again if the US drug pricing bill becomes law.

NASH reimbursement — The drug pricing legislation under consideration in Congress could change the development strategy for products targeting liver disease and every other condition. • Source: Nielsen Hobbs; the Pink Sheet | Shutterstock images

Intercept Pharmaceuticals, Inc. is ready to try again with a potential blockbuster label expansion for its liver drug obeticholic acid as a treatment for non-alcoholic steatohepatitis (NASH).

Whether the second attempt at approval – the first sNDA for NASH was rejected by the US Food & Drug...